Bendamustine for the treatment of non-Hodgkin lymphoma

At the iwNHL 2014, Dr Mathias Rummel (Justus-Liebig University-Hospital, Gießen, Germany) describes his research investigating the use of bendamustine plus rituximab in treating indolent and mantle cell lymphomas, highlighting the clinical implications of his long-term findings. He also presents an overview of the progress in other treatment strategies. He concludes with a description of the current and prospective treatment strategies for indolent lymphomas.